662 related articles for article (PubMed ID: 3815359)
1. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Kramer RA; Greene K; Ahmad S; Vistica DT
Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
[TBL] [Abstract][Full Text] [Related]
2. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
Ono K; Shrieve DC
J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
Smith AC; Liao JT; Page JG; Wientjes MG; Grieshaber CK
Cancer Res; 1989 Oct; 49(19):5385-91. PubMed ID: 2766304
[TBL] [Abstract][Full Text] [Related]
4. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
[TBL] [Abstract][Full Text] [Related]
5. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
Anderson CP; Reynolds CP
Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
[TBL] [Abstract][Full Text] [Related]
6. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
Soble MJ; Dorr RT
Anticancer Res; 1988; 8(1):17-22. PubMed ID: 3358633
[TBL] [Abstract][Full Text] [Related]
7. Effects of L-phenylalanine mustard and L-buthionine sulfoximine on murine and human hematopoietic progenitor cells in vitro.
Du DL; Volpe DA; Grieshaber CK; Murphy MJ
Cancer Res; 1990 Jul; 50(13):4038-43. PubMed ID: 2354454
[TBL] [Abstract][Full Text] [Related]
8. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
Liebmann JE; Hahn SM; Cook JA; Lipschultz C; Mitchell JB; Kaufman DC
Cancer Res; 1993 May; 53(9):2066-70. PubMed ID: 8097674
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
Chen G; Zeller WJ
Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
[TBL] [Abstract][Full Text] [Related]
10. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines.
Peters RH; Jollow DJ; Stuart RK
Cancer Res; 1991 May; 51(10):2536-41. PubMed ID: 2021933
[TBL] [Abstract][Full Text] [Related]
11. Glutathione depletion by DL-buthionine-SR-sulfoximine (BSO) potentiates X-ray-induced chromosome lesions after liquid holding recovery.
Bertsche U; Schorn H
Radiat Res; 1986 Mar; 105(3):351-69. PubMed ID: 3754339
[TBL] [Abstract][Full Text] [Related]
12. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
13. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
Skapek SX; Colvin OM; Griffith OW; Elion GB; Bigner DD; Friedman HS
Cancer Res; 1988 May; 48(10):2764-7. PubMed ID: 3359437
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells.
Dusre L; Mimnaugh EG; Myers CE; Sinha BK
Cancer Res; 1989 Feb; 49(3):511-5. PubMed ID: 2535960
[TBL] [Abstract][Full Text] [Related]
15. Intercellular transfer of drug resistance.
Frankfurt OS; Seckinger D; Sugarbaker EV
Cancer Res; 1991 Feb; 51(4):1190-5. PubMed ID: 1997161
[TBL] [Abstract][Full Text] [Related]
16. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067.
Xu BH; Singh SV
Cancer Res; 1992 Dec; 52(23):6666-70. PubMed ID: 1423311
[TBL] [Abstract][Full Text] [Related]
17. Selective enhancement of hypoxic cell killing by melphalan via thiol depletion: in vitro studies with hypoxic cell sensitizers and buthionine sulfoximine.
Roizin-Towle L
J Natl Cancer Inst; 1985 Jan; 74(1):151-7. PubMed ID: 3155814
[TBL] [Abstract][Full Text] [Related]
18. Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells.
Dethlefsen LA; Lehman CM; Biaglow JE; Peck VM
Radiat Res; 1988 May; 114(2):215-24. PubMed ID: 3375425
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
O'Dwyer PJ; Hamilton TC; LaCreta FP; Gallo JM; Kilpatrick D; Halbherr T; Brennan J; Bookman MA; Hoffman J; Young RC; Comis RL; Ozols RF
J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205
[TBL] [Abstract][Full Text] [Related]
20. Effects of glutathione depletion by buthionine sulfoximine on radiosensitization by oxygen and misonidazole in vitro.
Shrieve DC; Denekamp J; Minchinton AI
Radiat Res; 1985 Jun; 102(3):283-94. PubMed ID: 4070545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]